Recent News

• 09.12.2025 - Sean McCutcheon
• 09.12.2025 - Sean McCutcheon
• 09.10.2025 - Metastatic Pancreatic Cancer Update
• 09.10.2025 - Metastatic Pancreatic Cancer Update
• 09.10.2025 - Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
• 09.10.2025 - Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
• 09.10.2025 - Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
• 09.08.2025 - Asthika Goonewardene
• 09.08.2025 - Asthika Goonewardene
• 08.19.2025 - Kelsey Goodwin

Recent Filings

• 09.11.2025 - 144 Report of proposed sale of securities
• 09.10.2025 - 8-K Current report
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2025 - 144 Report of proposed sale of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors